stem cell therapy market. For instance, in January 2010, the Augusta University (U.S) initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2019. Cerebral palsy is a severe, lifelong disability disease that affects children, and has various signs and symptoms such as poor coordination, stiff muscles, and tremors.
Moreover, increasing product launches by key players is expected to boost demand for stem cell therapy over the forecast period. For instance, in March 2017, Osiris Therapeutics, Inc., launched their product called Prestige Lyotechnology for long-term storage of living cells and tissues. Prestige Lyotechnology mainly focuses on placental products such as stem cells. Such technological advancements are expected to support the growth of the stem cell therapy market.
North America stem cell therapy market is expected to account for the largest market share, owing to increasing research and development activities in the region. For instance, in February 2018, City of Hope Medical Center, U.S initiated clinical phase I study of the pre-transplant immunosuppressive therapy for haploidentical transplants in patients with sickle cell disease. The study is expected to complete in February 2023.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2848
Major players operating in the global stem cell therapy market include Osiris Therapeutics, Inc. Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc., and Fibrocell Science, Inc.
Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market. For instance, in May 2018, Procella Therapeutics and Smartwise Medtech Company collaborated with AstraZeneca Pharmaceuticals. Under this collaboration, AstraZeneca was able to utilize Procella Therapeutics’ stem cell technology for development of stem cell therapies in cardiovascular diseases.
Stem cell banks facilitate extraction, processing of stem cells, and storage of stem cells for future use. Increasing launches of stem cell banks is expected to boost the stem cell therapy market growth. For instance, in January 2018, Lifecell Biotechnology launched a stem cell bank in India, which preserves and provides umbilical cord stem cells for stem cell transplantation. In a stem cell transplantation therapy damaged, diseased cell or tissues are replaced or repaired by using stem cells. Hence, stem cell banking is expected to support the stem cell therapy market growth.
Browse the Full Report: https://www.coherentmarketinsights.com/market-insight/stem-cell-therapy-market-2848
Increasing number of approvals from regulatory authorities are expected to drive growth of the global stem cell therapy market. For instance, in March 2018, TiGenix NV and Takeda Pharmaceuticals received central marketing authorization from the European Commission to market Alofisel (an allogeneic stem cell therapy) in Europe. This therapy is used for the treatment of complex perianal fistulas in adult patients.
Key players in the stem cell therapy market are focused on launching new products in order to strengthen their position in the market. For instance, in November 2015, Osiris Therapeutics, Inc. launched its new product Stravix. Stravix is a viable cryopreserved human placental tissue, and is a used in soft tissue repair therapies.
Moreover, increasing research and development activities around the world are expected to propel the stem cell therapy market growth. For instance, in December 2017, Mayo Clinic initiated the clinical phase I study on safety and feasibility of mesenchymal stem cells therapy in patients with recent intracerebral hemorrhage. This therapy is used for treating acute spontaneous hemorrhagic stroke. The study is expected to complete in December 2020.
Furthermore, In October 2017, University of California, San Francisco, U.S. initiated the clinical phase I study to evaluate the safety and efficacy of “In Utero Hematopoietic Stem Cell Transplantation” for treatment of fetuses with alpha thalassemia major. This is a blood disorder which reduces production of hemoglobin. The study is expected to complete in February 2024.
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2848
About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com